Apogenix progresses study of cancer agent

Wednesday 9 June 2010

Apogenix GmbH of Heidelberg, Germany has begun recruitment for a Phase 2 study of a compound for treating glioblastoma multiforme, the most aggressive type of primary brain tumour. Interim results are expected in the first half of 2011.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany